APP and Alzheimer disease: Together, we found that long‐term dosing with BD10‐2 imparts transcriptomic shifts in neuronal, microglial, and oligodendroglial, human‐mouse AD co‐expression modules that are otherwise smaller or absent when examining APP effect alone.